Prostatic cancer. Transcortin levels during treatment with estramustine phosphate.
Plasma transcortin and cortisol levels, which are significantly elevated by estrogens, were determinied in a group of patients with prostatic cancer who were on estramustine phosphate (Estracyt) therapy.  In a series of 44 male patients studied transcortin and corticol levels became elevated above normal and were maintained at these high levels as long as the patients were on estramustine phosphate therapy.  The levels observed in this study may serve as reliable indices to monitor patients who are on this drug.
D004054:Diethylstilbestrol / Q000627:therapeutic use; D004961:Estramustine / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D005262:Feminization / Q000139:chemically induced; D006801:Humans; D006854:Hydrocortisone / Q000097:blood; D008297:Male; D008954:Models, Biological; D009325:Nausea; D009588:Nitrogen Mustard Compounds / Q000627:therapeutic use*; D011471:Prostatic Neoplasms / Q000097:blood / Q000188:drug therapy*; D014156:Transcortin / Q000032:analysis* / Q000096:biosynthesis
D009588:Nitrogen Mustard Compounds; D004961:Estramustine; D004054:Diethylstilbestrol; D014156:Transcortin; D006854:Hydrocortisone